**Abstracts**

### P539 PREVALENCE OF CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE AMONG YOUNG MSM IN MOROCCO

Amina Hanafi1, Bahija Bellaji1, Sanae Jemmene1, Nabilah Soria2, Aziza Bennani1, Latifa Gharqui1, Houssine Rhilani1, Kamal Alam1, Mohamed Rhajouci1. 1Institut National d’Hygiène, Ministry of Health Morocco, Rabat, Morocco; 2University Hospital Laboratory, Marrakech, Morocco; 3National STI/AIDS Program – Directorate of Epidemiology, Ministry of Health Morocco, Rabat, Morocco; 4UNAIDS – Morocco, Rabat, Morocco.


**Background** Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are the most common pathogens causing genital tract infections. They cause a significant global morbidity and mortality and have been associated with increased risk of HIV transmission, mainly among key populations fueling STIs and HIV. Men who have sex with men (MSM) has been classified by the Moroccan National AIDS Program (NAP) as a vulnerable group with higher burden of STIs. The aim of the present study is to assess the prevalence of CT and NG among young MSM in Marrakech.

**Methods** From October to December 2017, a total of 238 MSM were enrolled in the study using Respondent-Driven Sampling (RDS). Access to this population was facilitated by an NGO evolving in the field of HIV and STIs, with extensive experience with hard-to-reach population. Eligible recruits were aged of 18 years and older and having lived in Marrakech for the previous six months. Socio-demographic and behavioral factors were collected using a structured questionnaire. CT and NG investigations were performed using the molecular test the Xpert CT/NG tests (Cepheid, USA) on anal swab samples.

**Results** The findings showed a prevalence of CT and NG of 9.24% (22/238) and 8.40% (20/238) respectively. A CT/NG coinfection was found in 3.36% (8/238) of cases. Fifty percent of MSM reported having passive anal sex with a male partner in the past six months and 44.1% have used Condom at the last passive anal sex.

**Conclusion** The prevalence of CT and NG among MSM in Marrakech has increased significantly compared to the results obtained in the first study conducted in 2010, which was 6.3% for CT and 2.4% for NG. These findings confirmed the need for the establishment and the expansion of programs targeting MSM in Morocco to strengthen the prevention and control of STIs among risky groups.

**Disclosure** No significant relationships.

### P540 HPV (SERO) PREVALENCE AMONG YOUNG MSM VISITING THE STI CLINIC: OPPORTUNITIES FOR TARGETED HPV VACCINATION

Petra Woestenberg, Birgit Van Benthem, Johannes Bogaards, Audrey King, Fiona Van Der Klei, Susan Leussink, Marianne Van Der Sande, Christian Hoebe. 1RIVM, Center for Infectious Disease Control, Bilthoven, Netherlands; 2Institute of Tropical Medicine, Department of Public Health, Antwerp, Belgium; 3Public Health Service South Limburg, Maastricht University Medical Center (MUMC), Sexual Health, Infectious Diseases and Environmental Health, Medical Microbiology, Care and Public Health Research Institute (CAPHR), Heerlen, Netherlands.

10.1136/sextrans-2019-sti.615

**Background** Because men who have sex with men (MSM) are disproportionally affected by human papillomavirus (HPV) related cancers, countries might consider targeted HPV vaccination for MSM. We assessed the prevalence of vaccine-preventable HPV types among young MSM visiting sexually transmitted infection (STI) clinics in the Netherlands.

**Methods** We used data from MSM included in the PASSYON study, a biennial cross-sectional study among STI clinic visitors aged 16–24 years that started in 2009 when girls-only HPV vaccination was introduced. MSM were asked to provide a penile and anal swab for HPV DNA testing (including the vaccine-preventable types HPV6/11/16/18/31/33/45/52/58) and blood for HPV antibody testing (HPV16/18/31/33/45/52/58).

**Results** We included 575 MSM with a median age of 22 years and a median of 15 lifetime partners. No trends in penile or anal HPV prevalence over time were seen. Of the 455 MSM with both swabs available, 79%, 62% and 53% were HPV DNA negative at both anatomic sites for HPV16/18, HPV6/11/16/18 and HPV6/11/16/18/31/33/45/52/58 respectively. Most of these MSM who were HPV DNA negative, were also seronegative (80% for HPV16/18 and 70% for HPV16/18/31/33/45/52/58).

**Conclusion** The HPV prevalence among MSM did not decline since girls-only vaccination was introduced indicating that MSM are unlikely to benefit from herd effects from girls-only vaccination. Because the majority of young MSM visiting the STI clinic were (sero)negative for HPV16/18, the most important oncogenic types in males, targeting this group for HPV vaccination could still be beneficial.

**Disclosure** No significant relationships.

### P541 TO POOL OR NOT TO POOL STI SAMPLES IN MSM USING PREP? RESULTS OF THE COHMSM-PREP STUDY (ANRS 12369 – EXPERTISE FRANCE)

Irith De Baetselier, Bea Vuyysteke, Issoufou Yaya, Amoumou Dagna, Souba Diandé, Jeff Yaka, Gerard Kadanga, Issa Traoré, Vicky Cuylaerts, Hilde Smet, Elias Dah, Ephrem Mensah, Bintou Dembele, Christian Laurent, Tania Crucitti. 1Institut de Tropical Medicine, Clinical Sciences, Antwerp, Belgium; 2Institute of Tropical Medicine, Department of Public Health, Antwerp, Belgium; 3IRD, INSERM, Montpellier, France; 4CHU-SO-LNR-TB, Lomé, Togo; 5LNR-TB, Ouagadougou, Burkina Faso; 6Espoir Vie Togo, Lomé, Togo; 7Association African Solidarité, Ouagadougou, Burkina Faso; 8Institute of Tropical Medicine, Antwerp, Belgium; 9ARCADISDA, Bamako, Mali; 10Institute of Tropical Medicine, Yaoundé, Cameroon.

10.1136/sextrans-2019-sti.616

**Background** Syndromic diagnosis of sexually transmitted infections (STIs) has shown its limits among MSM using PrEP due to the many asymptomatic infections. However, testing three biological sites (urethra, pharynx and anorectum) is expensive. Our objective was to implement and to evaluate a pooling method using the locally available GeneXpert instrument to test for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in the framework of the West-African CohMSM-PreP study (Togo and Burkina Faso).

**Methods** Duplicate pharyngeal (P) and anorectal (A) e-swabs and first-void urine (U) samples were taken from every participant (n=192 in total). A specimen pool per participant (400 μL of each sample) was made and tested using the Xpert CT/NG kit. If positive, the individual samples were tested to confirm the site of infection. Duplicate individual samples were also tested for evaluation purposes using the Abbott CT/NG molecular technique and in-house qPCR.

**Results** A total of 32 CT infections (10U-20A-2P) and 34 NG infections (5U-19A-10P) were found. Twelve results obtained by testing of the pools were discordant from the individual samples.
testing using Abbott CT/NG. When unpooling the samples, one discordant result was solved. Three CT infections (1 in each sampling site) and four NG infections (2A and 2P) were missed; one CT (P) and three NG (A) infection were found to be false positive (one in each sampling site). This converts into a respective sensitivity and specificity of 91.2% (95%CI: 76.3–98.1%) and 99.8% (95%CI: 99.0–100.0%) for CT and 88.6% (95%CI: 73.3–96.8%) and 99.4% (95%: 98.3–99.9%) for NG of the pooling strategy. Cohen’s Kappa agreement was 0.94 for CT and 0.89 for NG which is an almost perfect agreement.

Conclusion We showed that this pooling strategy performs well using the FDA approved point-of-care assay GeneXpert. This may be a very cost-effective strategy and also feasible, as the assay is widespread throughout the African continent for tuberculosis testing.

Disclosure No significant relationships.

### Abstracts

**P542 **

**PREVALENCE OF STIS AMONG MSM INITIATING PREP IN WEST-AFRICA (COHMSM-PREP ANRS 12369 – EXPERTISE FRANCE)**

1Irith De Baetsele*, 2Tania Crucitti, 3Isaouf Yaya, 4Bintou Dembele, 5Ephrem Mensah, 6Elias Dah, 7Amadou Koné, 8Hortense Fayé-Ketté, 9Souba Diandé, 8Alain Yeo, 10Anoumou Dagnra, 3Christian Laurent, 11Bea Vuykstoke. 1Institute of Tropical Medicine, Clinical Sciences, Antwerp, Belgium; 2Institut Pasteur du Cameroun, Yaoundé, Cameroon; 3IRD, INSERM, Montpellier, France; 4ARCAD/SDA, Bamako, Mali; 5Esopir Vie Togo, Lomé, Togo; 6Association African Solidarité, Ouagadougou, Burkina Faso; 7SEREO/UERC, USTTB, Bamako, Mali; 8Institut Pasteur Côte d’Ivoire, Abidjan, Côte d’Ivoire; 9LNR-TB, Ouagadougou, Burkina Faso; 10CHU-SO-LNR-TB, Lomé, Togo; 11Institute of Tropical Medicine, Department of Public Health, Antwerp, Belgium

10.1136/sextrans-2019-sti.617

**Background** Men who have sex with men (MSM) coming forward for Pre-Exposure Prophylaxis (PrEP) are at high risk for HIV and other Sexually Transmitted Infections (STIs). However, little is known about the prevalence of STIs among MSM in West-Africa. Yet, understanding the STI epidemic can be effective in reducing HIV incidence and gonorrhoea prevalence among MSM and can be cost-effective, even if all PrEP users prefer the daily regime. Monitoring of PrEP users prefer event-driven PrEP and they use half the amount of PrEP pills used by daily users. We assumed PrEP effectiveness was 86% regardless of regimen. Simulated outcomes of the transmission model were used in an economic model to calculate costs, quality-adjusted life-years (QALY), and incremental cost-effectiveness ratios (ICER), over 2018–2027, taking a healthcare payer perspective. An ICER less than €20,000 per QALY gained was considered cost-effective.

**Results** PrEP resulted in 3,486 HIV infections averted and 1,482 QALYs gained over 2018–2027. Gonorrhoea prevalence dropped from 0.782% in 2017 to 0.023% in 2027. When offering both daily and event-driven PrEP, the costs for PrEP medication were €19 million over 2018–2027. This resulted in less total costs than when no PrEP is offered, making this programme cost-saving. With only daily PrEP, the costs for PrEP medication were €22 million over 2018–2027, making this programme cost-effective with a mean ICER of €217.40 per QALY gained.

**Conclusion** The PrEP programme (including STI monitoring) can be effective in reducing HIV incidence and gonorrhoea prevalence among MSM and can be cost-effective, even if all PrEP users prefer the daily regime. Monitoring of PrEP users can result in reductions in prevalence of STIs being monitored. Acknowledgements: AIDSfonds (2014037), ZonMw (522002003).

**Disclosure** No significant relationships.